Program
Propylene Glycol
Also written as “Propylene Glycol (0.6%)”, “Nanodrop®” and “Propylene Glycol, 0.6% eye drops”.
Its studies are mostly in Dry Eye Syndromes, led by 3 companies.
Drug pagePropylene Glycol: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alcon | 10 open or running | no phasesince Oct 18, 2013 | Oct 18, 2013 | none ahead |
| Andover Research Eye Instituteits history only | 11 open or running | phase 4since Jun 24, 2026 | Jun 24, 2026 | none ahead |
| Laboratorios Sophia S.A de C.V.its history only | 10 open or running | phase 2since Sep 30, 2019 | Sep 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alcon only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2013First study: no phase study in Dry Eye SyndromesFirst studyNCT01967147 · 279 enrolled
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Alcon leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01967147Dry Eye Syndromes | – | Completed | Jan 2015 | 279 |
How it is read
Names in the registry
- “Propylene Glycol (0.6%)”, 1 entry
- “Nanodrop®”, 1 entry
- “Propylene Glycol, 0.6% eye drops”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.